Combination Therapy

Nanobomb Plus Immunotherapy Combination Cancer therapy

The Nanobomb Plus Immunotherapy approach represents a ground-breaking cancer treatment that merges nano technology, viral oncolysis, and checkpoint blockade immunotherapy. This innovative platform uses dual-function nanoparticles, engineered as Nanobombs, to physically disrupt tumour cells, deliver viral agents, and release tumour-specific antigens. It promotes cancer cell death through oxidative stress, further boosting the immunogenicity of tumours. The immune system, activated by the release of antigens and enhanced with checkpoint inhibitors, sustains an aggressive and long-lasting response against cancer cells. This multi-modal approach exploits multiple vulnerabilities within tumours, providing an advanced solution for patients who are unresponsive to conventional treatments.

Our Vision: Nanobomb Plus

Imagine a world where cancer no longer means fear, suffering, or death.
With Nanobomb Plus, we envision a future where tumors are shattered precisely at the source, without harming healthy tissues or debilitating side effects while at the same time our combination therapy will activate natural immunity pathways to provide systemic therapy to destroy metastatic cancers. An unmet clinical need.
This is Innovation through Transformation in how we fight cancer. Together, we can make it happen — for millions of patients, for future generations, for humanity.
The time is now. The technology is ready. The impact is global.

Competitive Advantages of Nanotherapy Plus

Clinical & Therapeutic Superiority

The next decade will see a sharp rise in cancer cases and deaths. The $ 500B+ oncology market demands scalable, effective solutions now!

Go-AI, incorporating Nanotherapy Plus, has discovered a combination therapy delivered by Nanobomb Plus without the use of “Chemotherapy”.

The “special protein”, along with checkpoint Inhibitors, creates an immunostimulatory microenvironment for targeted and localized cancer cell killing, while also providing systemic protection. A clear breakthrough in Precision Oncology + Systemic Oncology.

Market Leadership: With the cancer therapeutics market projected to hit $232 billion by 2026, "chemo-free" solutions capture the highest-value segment in Precision Oncology. Nanotherapy Plus is poised to make an impact.

Competitive Advantages of Nanobomb Plus

Precision Targeting: 🎯 Unlike the "scatter-gun" approach of chemo, our combination therapy works efficaciously to activate the pathways of natural immunity to identify and destroy only cancer cells.

Overcoming Resistance: Many tumors develop "chemo-resistance.“. Nanobomb Plus, a non-toxic therapy, overcomes resistance through an immunostimulatory environment that leads to “systemic memory”.

Combination therapy without chemotherapy drugs: While conventional cancer therapy will continue to use chemotherapy drugs as one of the primary treatments, our non-toxic Nanobomb Plus combination therapy does not include the use of chemotherapy drugs.

Eliminating toxicity: Our primary strategy is to improve the delivery and presentation of biologics with Nanobomb Plus delivered directly to the tumor site, which delivery route also serves to eliminate toxicity if delivered by any other routes.

Immune Memory: Nanobomb Plus "trains" the immune system to remember the cancer (a systemic primer: acts as an in situ vaccine), providing long-term systemic protection and significantly reducing the risk of recurrence.

Higher Success Rates: 📈 Targeted therapies have shown success rates as high as 80% in specific cases, compared to the traditional 30% average for systemic chemotherapy. This is a clear advantage of Nanobomb Plus without the debilitating effects of Chemotherapy. Better Quality of Life for Patients!

Pre-clinical Studies on Nanobombs

on BT474 Breast Cancer Cells

Controlled Nanobomb Explosions with Laser Light

Combination Therapy

Address

Contacts

Links